The Society for Women’s Health Research will celebrate advancements and innovations in women’s health by honoring three leaders for their contributions to the field at SWHR’s 29th Annual Awards Dinner on May 1 at the InterContinental Washington DC – The Wharf.
The Society for Women’s Health Research announced the election of two new members to its Board of Directors: Dr. Linda G. Griffith, professor of biological engineering at the Massachusetts Institute of Technology (MIT), and Dr. Michael Ybarra, vice president of medical affairs and strategic alliances at the Pharmaceutical Research and Manufacturers of America (PhRMA).
“Dr. Griffith is an impassioned advocate for innovations in women’s health, as evidenced by her efforts to tackle difficult and understudied areas of women’s health research,” SWHR President and CEO Dr. Amy M. Miller said. “Dr. Ybarra’s expertise in partnership-building will greatly benefit SWHR as we look to collaborate with organizations whose missions align with our own. We are pleased that Dr. Griffith and Dr. Ybarra have agreed to join our Board to help further our work in eliminating imbalances in care for women.”
Griffith is a professor of biological engineering and director of the Center for Gynepathology Research at MIT. She received a bachelor’s degree from Georgia Tech and a PhD degree from the University of California at Berkeley, both in chemical engineering. She is a member of the National Academy of Engineering and the recipient of a MacArthur Foundation Fellowship.
Her research encompasses molecular-to-systems level analysis, design and synthesis of biomaterials, scaffolds, devices and micro-organs for a range of applications in regenerative medicine, tissue engineering, and in vitro drug development. A central theme is connecting the experimental systems to systems biology measurements. The Griffith lab leads a substantial program to build the “Human Physiome on a Chip,” funded by DARPA and NIH. In this program, 10 microphysiological systems, including liver, gut, lung, and reproductive systems, are interconnected in a physiologically relevant manner. Griffith is also a member of SWHR’s Estrogen-Driven Diseases Network as both an endometriosis patient and a researcher whose work in endometriosis has been recognized by NIH’s Office of Research on Women’s Health as well as the Endometriosis Foundation of America.
Ybarra is a board-certified emergency physician and vice president of medical affairs and strategic alliances at PhRMA, where he oversees outreach to stakeholder organizations on federal advocacy issues. He is a graduate of Stanford University and Georgetown University School of Medicine and completed his residency training in emergency medicine at MedStar Washington Hospital Center. In addition to his advocacy work, he continues to practice clinically in the emergency department at MedStar Georgetown University Hospital.
A full list of the SWHR Board of Directors is available here.
Science is telling us more clearly all the time that we are setting ourselves up for failure by ignoring sleep as a critical part of the equation for good health.
A growing body of evidence shows women may have an increased risk of heart disease in the decades following a pregnancy in which they suffered from complications such as gestational diabetes or preeclampsia.
An SWHR working group published an expert review that identifies areas of need to improve a woman’s diagnosis, treatment, and access to quality care, as well as highlights priorities for the future of endometriosis research and care.
The most common, most underdiagnosed, and most undertreated pregnancy-related complication in the United States is perinatal depression — depression that occurs during pregnancy or within the first year after delivery. An estimated 10 to 20 percent of new mothers experience perinatal depression (a more inclusive term than postpartum depression), with half of these women going undiagnosed and untreated.
The Society for Women’s Health Research (SWHR) is pleased to announced the election of Alan Wright, MD, MPH, chief medical officer at Roche Diagnostics Corp., to its Board of Directors.
In her 22 years at the Food and Drug Administration, Marsha B. Henderson has had a profound influence on the advancement of women’s health research. When she retires at the end of this year, the FDA will surely feel the absence of this dedicated advocate and her leadership as FDA’s associate commissioner for women’s health and director of the Office of Women’s Health (OWH).